NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Price, News & Analysis

$5.85
+0.13 (+2.27%)
(As of 04/22/2024 ET)
Today's Range
$5.71
$5.94
50-Day Range
$5.72
$8.86
52-Week Range
$5.25
$22.75
Volume
1.10 million shs
Average Volume
1.24 million shs
Market Capitalization
$445.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.85

Travere Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
203.0% Upside
$17.85 Price Target
Short Interest
Bearish
13.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Travere Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$419,773 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.10) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

706th out of 907 stocks

Pharmaceutical Preparations Industry

329th out of 428 stocks

TVTX stock logo

About Travere Therapeutics Stock (NASDAQ:TVTX)

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Stock Price History

TVTX Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
TVTX Mar 2024 30.000 call
See More Headlines
Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TVTX
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.85
High Stock Price Target
$35.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+210.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$-111,400,000.00
Pretax Margin
-258.96%

Debt

Sales & Book Value

Annual Sales
$145.24 million
Book Value
$2.67 per share

Miscellaneous

Free Float
73,019,000
Market Cap
$436.87 million
Optionable
Optionable
Beta
0.58
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

TVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TVTX shares.
View TVTX analyst ratings
or view top-rated stocks.

What is Travere Therapeutics' stock price target for 2024?

15 Wall Street research analysts have issued 1-year price targets for Travere Therapeutics' shares. Their TVTX share price targets range from $9.00 to $35.00. On average, they predict the company's share price to reach $17.85 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price.
View analysts price targets for TVTX
or view top-rated stocks among Wall Street analysts.

How have TVTX shares performed in 2024?

Travere Therapeutics' stock was trading at $8.99 on January 1st, 2024. Since then, TVTX shares have decreased by 34.5% and is now trading at $5.89.
View the best growth stocks for 2024 here
.

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TVTX earnings forecast
.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its earnings results on Thursday, February, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.11. The company earned $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%.

What ETF holds Travere Therapeutics' stock?

Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.52% of its portfolio.

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends
.

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TVTX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners